Dr Peter Abel
![image overlay](data:image/svg+xml,%3Csvg width="223" height="223" xmlns="http://www.w3.org/2000/svg" version="1.1"/%3E)
Pete completed his first degree at Leeds University which was a BSc (Hons) in Genetics in 1990. He then worked as a Biomedical Scientist for several North West NHS trusts and completed a Masters qualification in 1993 at Manchester Metropolitan University. This was a Fellowship in Haematology award and allowed him to further his career in Biomedical Science.
Pete is course leader for the IBMS accredited and HCPC approved PTP course Healthcare Science. This course is the government-approved route for eligibility to join the register as a Biomedical Scientist. Pete also has the role of placement supervisor that involves co-ordinating student's work experience with local NHS trusts. His main area of expertise is haematology, immunology and genetics and teaches both under and postgraduate students. His area of research is in neuro-oncology and he is interested in immunosuppression, blood-borne biomarkers to enable diagnosis of brain tumours and novel targets for CAR-T therapy. Pete completed his PhD at UCLan in 2018.
Pete completed his first degree at Leeds University which was a BSc(Hons) in Genetics in 1990. He then worked as a Biomedical Scientist for several North West NHS trusts encompassing all areas of haematology including lymphoproliferative disorders and therapy, anticoagulation and blood transfusion. During his time at UCLan Pete has specialised his research in the area of neuro-oncology joining the Brain Tumour North West collaboration of research teams. He also has founded an international collaboration with Kansas University Medical Centre, jointly supervising post-graduate students with the US team.
- PhD Neuro-oncology, University of Central Lancashire, 2018 l Fellowship masters Haematology, Manchester Metropolitan University 1993 l BSc (Hons) Genetics, Leeds University, 1990
- Haematology l Immunology l Genetics l Evolution l
- Fellow of the Institute of Biomedical Science
Pete is interested in discovering and validating blood-borne biomarkers for glioma diagnosis to enable more efficient screening and diagnostic procedures to allow earlier therapy. The aims of this research are to investigate and evaluate a range of potential biomarkers measureable in blood to aid diagnosis of a brain tumour. This work is important as current methods of diagnosis are invasive requiring hospitalisation. If a blood test could be developed, then this would improve patient outcome, reduce costs and open up the possibility of screening which would greatly improve the speed of diagnosis. Pete is also interested in the research of novel targets for CAR-T therapy, an exciting prospect in immunotherapy, in both glioma and myeloma. This involves genetically engineering a specific white blood cell against a target molecule related to the cancer cell and has had great success in leukaemia treatment. He has set up a collaboration with Kansas University Medical Centre, The Christie NHS foundation trust and Brain Tumour North West to supervise a PhD student in this area.
Use the links below to view their profiles:
- Brain Tumour North West
- Kansas University Medical Centre
- Novel Targets for CAR-T therapy in Glioma and Myeloma
Telephone:44 (0) 1772 895828
Email: Email:Dr Peter Abel
Use the links below to view their profiles: